News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...
In an MRI substudy, the researchers found that survodutide improved body composition and liver fat content, with a 34% ...
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat ...
Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...
Company announcement No. 21 / 2026Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and ...
Parenting disagreements happen in every family, even in the animal kingdom. In a dramatic wildlife video captured by TikToker ...
News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...
New data highlight the potential benefits of survodutide, a once-weekly injectable therapy targeting both the glucagon and glucagon-like peptide-1 (GLP-1) receptors in individuals with obesity and ...
Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.
The Manual on MSN
Girard-Perregaux Celebrates 50 Years of the Laureato, an Iconic Sports Watch, With Four New Models
Girard-Perregaux has launched the Laureato Fifty collection, commemorating five decades of the Laureato, the Swiss maison’s ...
Boehringer Ingelheim said its experimental obesity drug survodutide significantly reduced harmful abdominal and liver fat in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results